GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins

GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins

We determined the molecular mechanisms by which the novel therapeutic GZ17-6.02 killed non-small cell lung cancer (NSCLC) cells. Erlotinib, afatinib, and osimertinib interacted with GZ17-6.02 to kill NSCLC cells expressing mutant EGFR proteins. GZ17-6.02 did not interact with any EGFR inhibitor to k...

Full description

Bibliographic Details
Main Authors: Laurence Booth, Cameron West, Robert P. Moore, Daniel Von Hoff, Paul Dent
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
GZ17-6.02
pemetrexed
osimertinib
NSCLC
resistance
autophagy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.711043/full

Similar Items

Similar Items